Raphael Briot1, James A Frank2, Tokujiro Uchida3, Jae W Lee4, Carolyn S Calfee2, Michael A Matthay5. 1. Cardiovascular Research Institute, University of California, San Francisco, CA. 2. Department of Medicine, University of California, San Francisco, CA. 3. Tokyo Medical and Dental University, Department of Anesthesiology, Tokyo, Japan. 4. Department of Anesthesia, University of California, San Francisco, CA. 5. Department of Medicine, University of California, San Francisco, CA. Electronic address: michael.matthay@ucsf.edu.
Abstract
BACKGROUND: Although alveolar epithelial injury is a major determinant of outcome in patients with acute lung injury, there is no reliable biological marker of alveolar epithelial injury. The primary objective was to determine whether elevated levels of the receptor for advanced glycation end products (RAGE), a marker of alveolar epithelial injury, reflect impaired alveolar fluid clearance (AFC) in an ex vivo perfused human lung preparation. A second objective was to determine whether levels of a marker of endothelial injury, von Willebrand factor antigen (vWF:Ag), are associated with impaired AFC. METHODS: Human lungs (N = 30) declined for transplantation by the California Transplant Donor Network were perfused at a constant pulmonary artery pressure of 12 mm Hg. Following rewarming to 36 degrees C, the lungs were inflated with a continuous positive airway pressure of 10 cm H(2)O. RAGE and vWF:Ag levels and AFC rates were then measured. RESULTS: The rate of AFC was inversely correlated with RAGE levels in the alveolar fluid (p < 0.005). Similarly, the concentration of RAGE in the alveolar fluid was significantly higher in lungs with submaximal AFC, defined in a prespecified analysis as <or= 14%/h, when compared with lungs with preserved AFC (median 0.82 vs 0.43 microg/mL; p < 0.05). In contrast, vWF:Ag levels did not correlate with the rate of AFC. CONCLUSIONS: RAGE may be a useful biological marker of alveolar epithelial injury and impaired AFC in donor lungs prior to transplant and perhaps in patients with acute lung injury.
BACKGROUND: Although alveolar epithelial injury is a major determinant of outcome in patients with acute lung injury, there is no reliable biological marker of alveolar epithelial injury. The primary objective was to determine whether elevated levels of the receptor for advanced glycation end products (RAGE), a marker of alveolar epithelial injury, reflect impaired alveolar fluid clearance (AFC) in an ex vivo perfused human lung preparation. A second objective was to determine whether levels of a marker of endothelial injury, von Willebrand factor antigen (vWF:Ag), are associated with impaired AFC. METHODS:Human lungs (N = 30) declined for transplantation by the California Transplant Donor Network were perfused at a constant pulmonary artery pressure of 12 mm Hg. Following rewarming to 36 degrees C, the lungs were inflated with a continuous positive airway pressure of 10 cm H(2)O. RAGE and vWF:Ag levels and AFC rates were then measured. RESULTS: The rate of AFC was inversely correlated with RAGE levels in the alveolar fluid (p < 0.005). Similarly, the concentration of RAGE in the alveolar fluid was significantly higher in lungs with submaximal AFC, defined in a prespecified analysis as <or= 14%/h, when compared with lungs with preserved AFC (median 0.82 vs 0.43 microg/mL; p < 0.05). In contrast, vWF:Ag levels did not correlate with the rate of AFC. CONCLUSIONS:RAGE may be a useful biological marker of alveolar epithelial injury and impaired AFC in donor lungs prior to transplant and perhaps in patients with acute lung injury.
Authors: Jonathan B Orens; Annette Boehler; Marc de Perrot; Marc Estenne; Allan R Glanville; Shaf Keshavjee; Robert Kotloff; Judith Morton; Sean M Studer; Dirk Van Raemdonck; Thomas Waddel; Gregory I Snell Journal: J Heart Lung Transplant Date: 2003-11 Impact factor: 10.247
Authors: J S Gammie; D R Stukus; S M Pham; B G Hattler; M F McGrath; K R McCurry; B P Griffith; R J Keenan Journal: Ann Thorac Surg Date: 1999-12 Impact factor: 4.330
Authors: S M Fiser; I L Kron; S M Long; A K Kaza; J A Kern; D C Cassada; D R Jones; M C Robbins; C G Tribble Journal: J Heart Lung Transplant Date: 2001-12 Impact factor: 10.247
Authors: S Fischer; A A Maclean; M Liu; J A Cardella; A S Slutsky; M Suga; J F Moreira; S Keshavjee Journal: Am J Respir Crit Care Med Date: 2000-11 Impact factor: 21.405
Authors: Nadir Yehya; Neal J Thomas; Nuala J Meyer; Jason D Christie; Robert A Berg; Susan S Margulies Journal: Intensive Care Med Date: 2016-04-21 Impact factor: 17.440
Authors: Peter J Smit; Weidun A Guo; Bruce A Davidson; Barbara A Mullan; Jadwiga D Helinski; Paul R Knight Journal: J Surg Res Date: 2014-04-08 Impact factor: 2.192
Authors: Adrian Doroszko; Thomas S Hurst; Dorota Polewicz; Jolanta Sawicka; Justyna Fert-Bober; David H Johnson; Grzegorz Sawicki Journal: Proteome Sci Date: 2010-01-29 Impact factor: 2.480